89bio Inc (ETNB) Sector
Health Care

(Current) $8.39
0.15 (1.82%) Open Price: 8.18


89bio Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardio-metabolic diseases. The company was founded in 2018 and is based in Herzliya, Israel. 89bio's lead product candidate is BIO89-100, a long-acting glycoPEGylated fibroblast growth factor 21 (FGF21) analogue, which is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a severe liver disease.


BIO89-100 is designed to target the underlying pathophysiology of NASH by addressing both hepatic and extra-hepatic manifestations of the disease. The drug is being developed as a potential first-line therapy for NASH and has demonstrated promising results in preclinical studies. BIO89-100 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug designation from the FDA and European Medicines Agency.


In addition to NASH, 89bio is exploring the potential of BIO89-100 in other liver and cardio-metabolic diseases, including severe hypertriglyceridemia and type 2 diabetes. The company is also developing a pipeline of product candidates based on its proprietary BIO89 platform, which is designed to enhance the pharmacokinetic and pharmacodynamic properties of proteins.


89bio is led by a team of experienced executives and scientists with a track record of successful drug development and commercialization. The company has raised significant capital through multiple rounds of financing, including a successful initial public offering in 2019. 89bio has also entered into partnerships with leading academic and industry partners to support the development of its product candidates.


As a clinical-stage biopharmaceutical company, 89bio faces significant risks and uncertainties in developing and commercializing its product candidates. These risks include clinical and regulatory risks, as well as risks related to competition, intellectual property, and financing. However, if successful, 89bio's innovative therapies could offer significant benefits to patients with liver and cardio-metabolic diseases, as well as create significant value for its shareholders.



(05/23/24) $8.18
(05/25/24) $8.24
(05/25/24) (Qty.)757,200
(05/23/24) $7.96
(05/23/24) $9.01
(05/19/24) $7.96
(05/05/24) $9.83
LetsEncrypt SSL Secure Stripe Payment Processing